Navigation Links
MiMedx Announces 2012 Results
Date:3/7/2013

ssory note which was converted to stock during the first quarter of 2013. During the year, the Company repaid the convertible debt related to the Surgical Biologics acquisition.

During the year, Contingent Warrants for the purchase of over three million shares of common stock with an exercise price of $.01 were voided per the terms of the 2012 Contingent Warrant agreement related to the trading price of the Company's Common Stock.

GAAP EarningsThe Company recorded a Net Loss of $7.7 million, or $0.09 per diluted common share, for the year ended December 31, 2012, a $2.5 million improvement as compared to the Net Loss of $10.2 million, or $0.14 per diluted common share, recorded for the year ended December 31, 2011. Included in the 2012 Net Loss  was a fair value adjustment of the earn-out liability of $1.6 million and a $1.8 million impairment of intangible assets related to our HydroFix® platform. Selling, general and administrative expenses increased due to the decision to build out the Company's direct sales force for government accounts, as well as to add key management and infrastructure related resources to support the Company's growth. Also included in the reported Net Loss for 2012 is non-cash related financing expense associated with the debt discount of $1.5 million for the full year of 2012 related to the Company's convertible notes. Additionally, other recurring non-cash items of $2.5 million in share-based compensation expense, $1.4 million in amortization expense, and $465,000 related to depreciation expense are included in the 2012 Net Loss from Operations.

The Company recorded a Net Loss of $1.6 million, or $0.02 per diluted common share, for the quarter ended December 31, 2012, a $1.0 million improvement as compared to the Net Loss from Operations of $2.6 million, or $0.03 per diluted common share, recorded for the quarter ended December 31, 2011. Included in the Net Loss is a charge of $247,000 related to the Surgical
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. MiMedx Group to Present at the 6th Annual OneMedForum
2. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
3. CCS Medical Announces Agreement with LifeScan
4. HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
5. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. DMH International Announces The Launch of TouchPACS
9. Psyche Systems Announces Availability of Toxicology LIS
10. Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
11. DDS Lab Announces Strategic Alliance with United Concordia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
(Date:1/14/2014)... Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre partner ... Virginia is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is ... husband, Dr. Cole Taylor , are avid scuba divers. "As ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Center is,seeking local residents with type 2 diabetes ... study evaluating an investigational,device, the TANTALUS System. Diabetes ... TANTALUS System is an implantable device that delivers ... The primary objective of the,randomized, double-blind controlled study ...
... successfully targets human leukemic stem cells, ATLANTA, ... has today presented data at the American Society,of ... promising,pre-clinical activity of a novel monoclonal antibody, in ... AML is an aggressive cancer of white blood ...
Cached Medicine Technology:Vanderbilt Medical Center Seeks Middle Tennesseans with Type 2 Diabetes Who are Overweight for National Clinical Trial 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 3
(Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2
... of Western Ontario has received over $603,000 from the Canadian ... a group of bacterial toxins leads to the development of ... is an associate professor in the Department of Microbiology and ... a scientist with the Lawson Health Research Institute. His ...
... (UV) radiation from sunlight may be associated with the ... to a study by researchers at the National Institute ... Institutes of Health. "This study found that women ... exposure when they developed an autoimmune muscle disease called ...
... July 30, 2009 Scientists at Washington University School ... in the liver that helps process fat and glucose. ... additive lecithin, and researchers speculate it may one day ... lipids and reduce risk for diabetes, hypertension or cardiovascular ...
... , , , ... $230,000 for Augie,s Quest, the fast-track research arm of the Muscular Dystrophy ... is dedicated to beating the previous goal by reaching $300,000 in donations ... Bally club now through August 31 and receive a free guest pass ...
... more apt to have joint replacement, study finds , THURSDAY, ... strongly predict the risk of hip and knee joint replacement ... , The research involved 912 healthy people in Italy, including ... or hip replacement between 1990 and 2005. Those with high ...
... , , , ... Mark Rodgers today announced that The Guardian House Alzheimer Care Facility ... commercial location to install the SamarionSolution, The Guardian House is a ... in caring for residents diagnosed with Alzheimer,s or dementia. The ...
Cached Medicine News:Health News:Sun exposure may trigger certain autoimmune diseases in women 2Health News:Food additive may one day help control blood lipids and reduce disease risk 2Health News:Food additive may one day help control blood lipids and reduce disease risk 3Health News:Bally Total Fitness Flexes Fundraising Muscle to Fight ALS 2Health News:Biomarker Could Predict Severe Osteoarthritis 2Health News:The First SamarionSolution Installed in Lake Charles Alzheimer's Facility 2
... An ISI technician carefully inspects your equipment ... any and all problems, and provides you with ... may be working within a tight budget so ... the intricate work of repair begins., , ISI ...
... ALT (GPT) powder reagent is intended for ... in serum. , Infinity ALT (GPT) powder ... stability once reconstituted and convenience, but ensures ... The reagent is suitable for manual use ...
... is a fully automated, versatile analyzer ... is increased due to the continuous loading ... A fully graphical user interface provides fast ... use. Konelab analyzers are delivered with full ...
Inquire...
Medicine Products: